Advertisement

CEN Case Reports

, Volume 7, Issue 1, pp 69–72 | Cite as

Serum sickness with refractory nephrotic syndrome following treatment with rituximab

  • Ryo Maeda
  • Yukihiko Kawasaki
  • Shinichiro Ohara
  • Kazuhide Suyama
  • Mitsuaki Hosoya
Case Report

Abstract

Rituximab (RTX) is effective for treating childhood refractory nephrotic syndrome (NS), such as steroid-dependent (SD), frequently relapsing (FR), and steroid-resistant (SR) NS. While RTX has been proven to be effective in treating SDNS, FRNS, and SRNS, it may cause serum sickness, a rare illness characterized by fever, rash, and arthralgia, 10–14 days after primary antigen exposure or within a few days after secondary antigen exposure, by producing human anti-chimeric antibodies (HACAs). A 17-year-old girl with refractory SDNS treated with RTX and oral cyclosporine A was admitted with fever and arthralgia 10 days after the fifth RTX dose was administered. After RTX was started when she was 14-years-old, SDNS remission was then achieved, and prednisolone was discontinued. Although antibiotics and non-steroidal anti-inflammatory agents were administered, fever and arthralgia continued. After various inspections and clinical course, we considered her as RTX-induced serum sickness (RISS). The patient had an elevated HACA level and was diagnosed with RISS. Fever and arthralgia disappeared 5 days after onset. To the best of our knowledge, this is the first reported case of RISS with NS. Fever, rash, and arthralgia after RTX administration can be the initial symptoms.

Keywords

Steroid-dependent nephrotic syndrome Refractory nephrotic syndrome Rituximab Human anti-chimeric antibodies Serum sickness 

Notes

Compliance with ethical standards

Conflict of interest

All the authors have declared that no conflict of interest exists.

Human and animal rights statement

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Kamei K, Ogura M, Sato M, Sako M, Iijima K, Ito S. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab. Pediatr Nephrol. 2016;31:89–95.CrossRefPubMedGoogle Scholar
  2. 2.
    Benz K, Dotsch J, Rascher W, Stachel D. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol. 2004;19:794–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol. 2005;20:1660–3.CrossRefPubMedGoogle Scholar
  4. 4.
    Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y, Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384:1273–81.CrossRefPubMedGoogle Scholar
  5. 5.
    Ito S, Kamei K, Ogura M, Udagawa T, Fujinaga S, Saito M, Sako M, Iijima K. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol. 2013;28:257–64.CrossRefPubMedGoogle Scholar
  6. 6.
    Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008;13:725–32.CrossRefPubMedGoogle Scholar
  7. 7.
    US National Library of Medicine. DailyMed. https://dailymed.nlm.nih.gov/dailymed/index.cfm Accessed 4 July 2017.
  8. 8.
    D’Arcy CA, Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum. 2001;44:1717–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Karmacharya P, Poudel D, Pathak R, Donato A, Ghimire S, Giri S, Aryal M, Bingham C. Rituximab-induced serum sickness: a systematic review. Semin Arthritis Rheum. 2015;45:334–40.CrossRefPubMedGoogle Scholar
  10. 10.
    Finger E, Scheinberg M. Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia. J Clin Rheumatol. 2007;13:94–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50:2580–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Goto S, Goto H, Tanoshima R, Kato H, Takahashi H, Sekiguchi O, Kai S. Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura. Int J Hematol. 2009;89:305–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Ahn YH, Kang HG, Lee JM, Choi HJ, Ha IS, Cheong HI. Development of antirituximab antibodies in children with nephrotic syndrome. Pediatr Nephrol. 2014;29:1461–4.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2018

Authors and Affiliations

  • Ryo Maeda
    • 1
  • Yukihiko Kawasaki
    • 1
  • Shinichiro Ohara
    • 1
  • Kazuhide Suyama
    • 1
  • Mitsuaki Hosoya
    • 1
  1. 1.Department of PediatricsFukushima Medical University School of MedicineFukushima CityJapan

Personalised recommendations